Salbutamol

Section: 25. Medicines acting on the respiratory tract  ➤ 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indication
Chronic obstructive pulmonary disease  
**ICD11 code:** CA22

### INN
Salbutamol

### Medicine type
Chemical agent

### List type
Core

### Formulations
- **Parenteral > General injections > IV:** 50 µg per mL in 5 mL ampoule (as sulfate)
- **Respiratory > Inhalation > aerosol:** 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
- **Respiratory > Inhalation > solution:** 5 mg per mL (as sulfate) for use in nebulizers

### EML status history
- First added in 2003 ([TRS 920](#))
- Changed in 2009 ([TRS 958](#))
- Changed in 2011 ([TRS 965](#))
- Changed in 2021 ([TRS 1035](#))

### Sex
All

### Age
Adolescents and adults

### Therapeutic alternatives
Terbutaline (ATC codes: R03CC03)

### Patent information
Patents have expired in most jurisdictions
Read more [about patents](#).

### Summary of evidence and Expert Committee recommendations
Following the review of square box listings on the EML and EMLc, the Expert Committee recommended terbutaline be specified as a therapeutic alternative under the square box listing for salbutamol on the EML for this indication.